Globes article that Gazit is buying more Ormat (ORA). We first reported this back in June when Gazit initiated a 12% stake in the clean-tech energy play. Gazit-Globe president Dori Segal told “Globes” that the company believes that cleantech has a long-term upside, and that it has unreserved confidence in Ormat and its executives.

Interesting interview with NICE Systems (NICE) product manager, Brian Spraetz, on the IP communications industry and what NICE is up to.

Forbes reporting that generic pharmaceuticals giant, TEVA (TEVA), spent over $1M on lobbying in 2007. Specifically, the article mentions that TEVA lobbied on funding for Food and Drug Administration’s generic drug office, patent reform legislation, the children’s health insurance program and trade issues.

Blue Square-Israel (BSI) leaks their intention to build-out a big-box presence in the Health Food/Organics market. Read IsraelNewsletter’s Zack Miller’s recent analysis of the move.

What a roller coaster. Protalix BioTherapeutics (PLX) treats first patient in a Phase III trial of prGCD, a drug in research to treat Gaucher Disease. We’ve seen this stock tank over 40% in last week’s trading.

Share with others:

Related posts

• No related posts.